carbamates has been researched along with Stroke in 10 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Excerpt | Relevance | Reference |
---|---|---|
" Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia." | 3.88 | Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke. ( Arai, AL; Choi, SH; Hallenbeck, J; Kang, B; Mou, Y; Silva, AC; Yen, CC, 2018) |
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
" Using a conditional transgenic mouse model, selective ablation of adult neural stem and progenitor cells in the subventricular zone induced a dramatic increase in morbidity and mortality of central nervous system disorders characterized by excitotoxicity-induced cell death accompanied by reactive inflammation, such as 4-aminopyridine-induced epilepsy and ischaemic stroke." | 3.78 | Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. ( Bacigaluppi, M; Bari, M; Brambilla, E; Butti, E; Cambiaghi, M; Cebrian Silla, A; Centonze, D; Comi, G; D'Adamo, P; De Ceglia, R; De Chiara, V; Garcia-Verdugo, JM; Leocani, L; Maccarrone, M; Martino, G; Musella, A; Muzio, L; Quattrini, A; Rossi, S; Teneud, L, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
van Seyen, M | 1 |
Samson, AD | 1 |
Cullen, L | 1 |
Eastick, K | 1 |
Knol, H | 1 |
Colbers, A | 1 |
Burger, DM | 1 |
Gnesin, F | 1 |
Thuesen, ACB | 1 |
Kähler, LKA | 1 |
Madsbad, S | 1 |
Hemmingsen, B | 1 |
Wang, F | 1 |
Han, J | 1 |
Higashimori, H | 1 |
Wang, J | 1 |
Liu, J | 1 |
Tong, L | 1 |
Yang, Y | 1 |
Dong, H | 1 |
Zhang, X | 1 |
Xiong, L | 1 |
Choi, SH | 1 |
Arai, AL | 1 |
Mou, Y | 1 |
Kang, B | 1 |
Yen, CC | 1 |
Hallenbeck, J | 1 |
Silva, AC | 1 |
Mogensen, UM | 1 |
Andersson, C | 1 |
Fosbøl, EL | 1 |
Schramm, TK | 1 |
Vaag, A | 1 |
Scheller, NM | 1 |
Torp-Pedersen, C | 1 |
Gislason, G | 1 |
Køber, L | 1 |
Xie, Y | 1 |
Li, Z | 1 |
Chabwine, JN | 1 |
Rossetti, AR | 1 |
Hirt, L | 1 |
Kuntzer, T | 1 |
Schluep, M | 1 |
Michel, P | 1 |
Démonet, JF | 1 |
du Pasquier, RA | 1 |
Vingerhoets, FG | 1 |
Butti, E | 1 |
Bacigaluppi, M | 1 |
Rossi, S | 1 |
Cambiaghi, M | 1 |
Bari, M | 1 |
Cebrian Silla, A | 1 |
Brambilla, E | 1 |
Musella, A | 1 |
De Ceglia, R | 1 |
Teneud, L | 1 |
De Chiara, V | 1 |
D'Adamo, P | 1 |
Garcia-Verdugo, JM | 1 |
Comi, G | 1 |
Muzio, L | 1 |
Quattrini, A | 1 |
Leocani, L | 1 |
Maccarrone, M | 1 |
Centonze, D | 1 |
Martino, G | 1 |
Erkinjuntti, T | 1 |
Román, G | 1 |
Gauthier, S | 1 |
Feldman, H | 1 |
Rockwood, K | 1 |
Linton, SD | 1 |
Aja, T | 1 |
Allegrini, PR | 1 |
Deckwerth, TL | 1 |
Diaz, JL | 1 |
Hengerer, B | 1 |
Herrmann, J | 1 |
Jahangiri, KG | 1 |
Kallen, J | 1 |
Karanewsky, DS | 1 |
Meduna, SP | 1 |
Nalley, K | 1 |
Robinson, ED | 1 |
Roggo, S | 1 |
Rovelli, G | 1 |
Sauter, A | 1 |
Sayers, RO | 1 |
Schmitz, A | 1 |
Smidt, R | 1 |
Ternansky, RJ | 1 |
Tomaselli, KJ | 1 |
Ullman, BR | 1 |
Wiessner, C | 1 |
Wu, JC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet[NCT03389061] | Phase 4 | 0 participants (Actual) | Interventional | 2018-04-01 | Withdrawn (stopped due to Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.) | ||
A Multicentric, Randomized, Open Label Study on Comparison of Pancreatic Beta Cell Recovery and Preservation in Type 2 Diabetic Patients Treated With DPP-4 Inhibitor (Vildagliptin) and Metformin[NCT02853630] | Phase 4 | 203 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus[NCT00679939] | Phase 4 | 226 participants (Actual) | Interventional | 2008-04-21 | Completed | ||
[NCT00396851] | 100 participants | Interventional | 2007-01-31 | Not yet recruiting | |||
Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes[NCT00099866] | Phase 3 | 570 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes[NCT00138567] | Phase 3 | 530 participants | Interventional | 2005-01-31 | Completed | ||
A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus[NCT03010683] | 60 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes[NCT00373178] | Phase 4 | 100 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Double Blind Comparison Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics With Metformin[NCT01001962] | Phase 4 | 1,054 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects[NCT00327015] | Phase 3 | 1,306 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control[NCT00103857] | Phase 3 | 1,208 participants (Actual) | Interventional | 2005-03-17 | Completed | ||
[NCT00035568] | Phase 4 | 0 participants | Interventional | 2002-02-28 | Completed | ||
A Multicenter, Register-based, Randomized, Controlled Trial Comparing Dapagliflozin With Metformin Treatment in Early Stage Type 2 Diabetes Patients by Assessing Mortality and Macro- and Microvascular Complications[NCT03982381] | Phase 4 | 2,067 participants (Actual) | Interventional | 2019-09-05 | Active, not recruiting | ||
Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)[NCT01126580] | Phase 3 | 807 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.120 |
Metformin in DB Period; Metformin in OL Period | -0.040 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 7.901 |
Metformin in DB Period; Metformin in OL Period | -5.025 |
Cortical thickness was measured by QCT. Change from Baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.082 |
Metformin in DB Period; Metformin in OL Period | -0.048 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -12.424 |
Metformin in DB Period; Metformin in OL Period | -10.244 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.117 |
Metformin in DB Period; Metformin in OL Period | -0.087 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -4.555 |
Metformin in DB Period; Metformin in OL Period | -7.553 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -8.007 |
Metformin in DB Period; Metformin in OL Period | -7.006 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline. (NCT00679939)
Timeframe: Baseline and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.95 |
Metformin in DB Period; Metformin in OL Period | -0.067 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from Week 52 was calculated as the Week 76 value minus the Week 52 value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | millimoles per Liter (mmol/L) (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 0.01 |
Metformin in DB Period; Metformin in OL Period | 0.00 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 0.09 |
Metformin in DB Period; Metformin in OL Period | 0.01 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 20.15 |
Metformin in DB Period; Metformin in OL Period | -10.73 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.08 |
Metformin in DB Period; Metformin in OL Period | 0.07 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 15.48 |
Metformin in DB Period; Metformin in OL Period | -17.59 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 0.11 |
Metformin in DB Period; Metformin in OL Period | -0.13 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 5.19 |
Metformin in DB Period; Metformin in OL Period | -6.24 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | millimeters (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 0.18 |
Metformin in DB Period; Metformin in OL Period | -0.05 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | mg/cm^3 (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 9.30 |
Metformin in DB Period; Metformin in OL Period | -4.92 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm. (NCT00679939)
Timeframe: Baseline and Week 52
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -1.24 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline and Week 76+10 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -1.91 |
Metformin in DB Period; Metformin in OL Period | 0.31 |
FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52+10 days and Week 76+10 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -0.07 |
Metformin in DB Period; Metformin in OL Period | -0.02 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 3.12 |
Metformin in DB Period; Metformin in OL Period | 1.56 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | -1.48 |
Metformin in DB Period; Metformin in OL Period | 2.04 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 14.02 |
Metformin in DB Period; Metformin in OL Period | -13.65 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 32.42 |
Metformin in DB Period; Metformin in OL Period | -7.80 |
BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) |
---|---|
Rosiglitazone in DB Period; Metformin in OL Period | 3.53 |
Metformin in DB Period; Metformin in OL Period | -2.11 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from baseline was calculated as the Week 52or Week 76 value minus the baseline value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | millimoles per Liter (mmol/L) (Mean) | |
---|---|---|
Week 52, n=73, 83 | Week 76, n=64, 75 | |
Metformin in DB Period; Metformin in OL Period | 0.03 | 0.04 |
Rosiglitazone in DB Period; Metformin in OL Period | 0.01 | 0.03 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=61, 65 | Week 52, GM, n=61, 65 | Week 52, GM + SE, n=61, 65 | Week 76, GM - SE, n=55, 58 | Week 76, GM, n=55, 58 | Week 76, GM + SE, n=55, 58 | |
Metformin in DB Period; Metformin in OL Period | -15.9 | -12.2 | -8.4 | -12.5 | -8.9 | -5.2 |
Rosiglitazone in DB Period; Metformin in OL Period | -27.9 | -24.7 | -21.4 | -21.3 | -18.1 | -14.6 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 52, GM - SE, BSAP, n=78, 84 | Week 52, GM, BSAP, n=78, 84 | Week 52, GM + SE, BSAP, n=78, 84 | Week 76, GM - SE, BSAP, n=64, 77 | Week 76, GM, BSAP, n=64, 77 | Week 76, GM + SE, BSAP, n=64, 77 | Week 52, GM - SE, P1NP, n=76, 83 | Week 52, GM, P1NP, n=76, 83 | Week 52, GM + SE, P1NP, n=76, 83 | Week 76 GM - SE, P1NP, n=63, 75 | Week 76, GM, P1NP, n=63, 75 | Week 76, GM + SE, P1NP, n=63, 75 | |
Metformin | -29.7 | -27.3 | -24.8 | -26.7 | -24.3 | -21.8 | -16.5 | -13.3 | -9.9 | -14.5 | -10.5 | -6.4 |
Rosiglitazone | -15.2 | -12.3 | -9.3 | -18.7 | -15.9 | -12.9 | 5.0 | 9.0 | 13.3 | -11.2 | -6.9 | -2.4 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=77, 84 | Week 52, GM, n=77, 84 | Week 52, GM + SE, n=77, 84 | Week 76, GM - SE, n=63, 77 | Week 76, GM, n=63, 77 | Week 76, GM + SE, n=63, 77 | |
Metformin in DB Period; Metformin in OL Period | -7.8 | -2.3 | 3.7 | -4.5 | 2.6 | 10.3 |
Rosiglitazone in DB Period; Metformin in OL Period | 11.3 | 18.1 | 25.4 | -19.5 | -13.1 | -6.1 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (orWeek 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |
---|---|---|
Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 0.64 | 0.39 |
Rosiglitazone in DB Period; Metformin in OL Period | -6.05 | -3.59 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52, Trabecular, n=32, 35 | Week 52, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 1.26 | 930.71 | 0.85 | 0.54 | 37.81 | -0.63 |
Rosiglitazone in DB Period; Metformin in OL Period | -4.35 | -161.59 | -1.85 | -0.29 | 81.29 | 1.45 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |
---|---|---|
Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | -1.27 | -0.11 |
Rosiglitazone in DB Period; Metformin in OL Period | 0.47 | -1.46 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 1.74 | 282.16 | 1.14 | 0.01 | 13.54 | -1.17 |
Rosiglitazone in DB Period; Metformin in OL Period | -4.11 | -84.08 | -3.42 | -3.11 | 24.46 | -1.32 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 0.58 | 0.91 | -0.20 | -0.61 | 2.27 | -1.60 |
Rosiglitazone in DB Period; Metformin in OL Period | -3.72 | -1.83 | -1.00 | -2.13 | -1.05 | -0.46 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days(or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |
---|---|---|
Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 5.05 | -4.78 |
Rosiglitazone in DB Period; Metformin in OL Period | -13.45 | -4.23 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 daysor Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days(or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 plus 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | -0.58 | 2.82 | -0.25 | -2.45 | 3.98 | -1.49 |
Rosiglitazone in DB Period; Metformin in OL Period | -6.56 | 3.59 | -1.91 | -4.97 | -0.85 | -0.93 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100% (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |
---|---|---|
Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31,30 | |
Metformin in DB Period; Metformin in OL Period | 1.00 | -1.50 |
Rosiglitazone in DB Period; Metformin in OL Period | -20.48 | -3.52 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | -0.03 | 5.57 | -0.66 | 1.07 | 10.24 | -1.30 |
Rosiglitazone in DB Period; Metformin in OL Period | -10.26 | 2.77 | -3.76 | -4.21 | 2.37 | -1.65 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (BMD at Week 52 + 30 days (orWeek 76 + 30 days) minus BMD at baseline)/BMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 52 + 30 days; Femoral neck (FN), n=32, 35 | Week 52 + 30 days; Total hip (TH), n=32, 35 | Week 52 + 30 days; Trochanter (Tro.), n=32, 35 | Week 52+30 days; Intertrochanter (Inter.),n=32, 35 | Week 76+30 days; Femoral neck (FN), n=31, 30 | Week 76 + 30 days; TH, n=31, 30 | Week 76 + 30 days; Tro., n=31, 30 | Week 76 + 30 days; Inter., n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 0.09 | 0.09 | -0.23 | 0.77 | -1.52 | -0.32 | -1.28 | 0.30 |
Rosiglitazone in DB Period; Metformin in OL Period | -2.39 | -3.39 | -4.53 | -3.36 | -1.98 | -2.11 | -2.86 | -1.66 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline and Week 52
Intervention | percent change (Mean) | |||
---|---|---|---|---|
Femoral neck, n=52, 54 | Total hip, n=52, 54 | Trochanter, n=52, 54 | Lumbar spine, n=51, 53 | |
Metformin in DB Period; Metformin in OL Period | 0.72 | -0.38 | -0.78 | 0.12 |
Rosiglitazone in DB Period; Metformin in OL Period | -1.24 | -0.77 | -0.21 | -1.21 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 + 10 days or Week 76 + 10 days was calculated as (BMD at Week 52 + 10 days (or Week 76 + 10 days ) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 10 days, and Week 76 + 10 days
Intervention | percent change (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 52 + 10 days; Femoral neck (FN), n=70, 78 | Week 52 + 10 days; Total hip (TH), n=70, 78 | Week 52 + 10 days; Trochanter (Tro.), n=70, 78 | Week 52 + 10 days; Lumbar spine (LS), n=70, 76 | Week 76 + 10 days; FN, n=65, 70 | Week 76 + 10 days; TH, n=65, 70 | Week 76 + 10 days; Tro., n=65, 70 | Week 76 + 10 days; LS, n=65, 71 | |
Metformin in DB Period; Metformin in OL Period | 0.22 | -0.72 | -1.04 | 0.04 | 0.31 | -0.83 | -1.35 | 0.85 |
Rosiglitazone in DB Period; Metformin in OL Period | -1.47 | -1.62 | -1.45 | -1.41 | -1.91 | -1.70 | -2.14 | -1.24 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (BMD at Week 52 + 30 days (or Week 76 + 30 days) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 52 + 30 days; Femoral neck (FN), n=77, 83 | Week 52 + 30 days; Total hip (TH), n=77, 83 | Week 52 + 30 days; Trochanter (Tro.), n=77, 83 | Week 52 + 30 days; Lumbar spine (LS), n=79, 81 | Week 76 + 30 days; FN, n=66, 74 | Week 76 + 30 days; TH, n=66, 74 | Week 76 + 30 days; Tro., n=66, 74 | Week 76 + 30 days; LS, n=66, 72 | |
Metformin in DB Period; Metformin in OL Period | 0.24 | -0.72 | -1.01 | 0.11 | 0.29 | -0.68 | -0.96 | 1.13 |
Rosiglitazone in DB Period; Metformin in OL Period | -1.59 | -1.79 | -1.83 | -1.60 | -2.05 | -1.79 | -2.53 | -1.15 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=64, 71 | Week 52, GM, n=64, 71 | Week 52, GM + SE, n=64, 71 | Week 76, GM - SE, n=56, 64 | Week 76, GM, n=56, 64 | Week 76, GM + SE, n=56, 64 | |
Metformin in DB Period; Metformin in OL Period | -25.9 | -22.0 | -17.8 | -26.2 | -20.8 | -15.0 |
Rosiglitazone in DB Period; Metformin in OL Period | -16.5 | -12.0 | -7.2 | -28.8 | -23.1 | -17.0 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 2.18 | -0.22 | 0.99 | 1.88 | 0.27 | 0.79 |
Rosiglitazone in DB Period; Metformin in OL Period | -3.47 | -4.26 | -0.76 | -0.92 | -3.09 | 0.41 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Baseline was calculated as (vBMD at Week 52+30 days (or Week 76+30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days; Integral, n=32, 35 | Week 52 + 30 days; Trabecular, n=32, 35 | Week 52 + 30 days; Cortical, n=32, 35 | Week 76 + 30 days; Integral, n=31, 30 | Week 76 + 30 days; Trabecular, n=31, 30 | Week 76 + 30 days; Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 0.99 | 0.21 | 0.52 | 0.85 | 0.70 | 0.50 |
Rosiglitazone in DB Period; Metformin in OL Period | -3.60 | -3.63 | -0.54 | -1.70 | -2.66 | 0.23 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
Week 52 + 30 days, Integral, n=32, 35 | Week 52 + 30 days, Trabecular, n=32, 35 | Week 52 + 30 days, Cortical, n=32, 35 | Week 76 + 30 days, Integral, n=31, 30 | Week 76 + 30 days, Trabecular, n=31, 30 | Week 76 + 30 days, Cortical, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | 0.01 | 0.67 | -0.18 | -0.93 | 0.92 | -0.64 |
Rosiglitazone in DB Period; Metformin in OL Period | -4.80 | -3.43 | -1.26 | -2.88 | -2.42 | -0.49 |
BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Baseline, Week 52 + 30 days, and Week 76 + 30 days
Intervention | percent change (Mean) | |
---|---|---|
Week 52 + 30 days, n=32, 35 | Week 76 + 30 days, n=31, 30 | |
Metformin in DB Period; Metformin in OL Period | -1.72 | -3.91 |
Rosiglitazone in DB Period; Metformin in OL Period | -6.71 | -5.15 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -7.7 | -3.2 | 1.5 |
Rosiglitazone in DB Period; Metformin in OL Period | -4.7 | 0.1 | 5.1 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
GM - SE, BSAP, n=64, 76 | GM, BSAP, n=64, 76 | GM + SE, BSAP, n=64, 76 | GM - SE, P1NP, n=63, 76 | GM, P1NP, n=63, 76 | GM + SE, P1NP, n=63, 76 | |
Metformin in DB Period; Metformin in OL Period | 4.3 | 8.0 | 11.8 | 3.2 | 7.0 | 11.0 |
Rosiglitazone in DB Period; Metformin in OL Period | -5.6 | -2.0 | 1.8 | -15.8 | -12.4 | -9.0 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | 2.2 | 8.4 | 14.9 |
Rosiglitazone in DB Period; Metformin in OL Period | -31.2 | -26.7 | -21.9 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | 0.38 | 260.13 | -1.64 |
Rosiglitazone in DB Period; Metformin in OL Period | 5.05 | -90.60 | 3.68 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -1.87 | 161.81 | -2.50 |
Rosiglitazone in DB Period; Metformin in OL Period | 1.47 | -39.81 | 2.67 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -1.37 | 2.21 | -1.30 |
Rosiglitazone in DB Period; Metformin in OL Period | 2.21 | 0.27 | 1.03 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -1.81 | 6.63 | -1.28 |
Rosiglitazone in DB Period; Metformin in OL Period | 2.96 | -2.78 | 1.19 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | 0.52 | -11.69 | -0.94 |
Rosiglitazone in DB Period; Metformin in OL Period | 8.29 | 36.05 | 2.17 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | |||
---|---|---|---|---|
percent change | Total hip | Trochanter | Intertrochanter | |
Metformin in DB Period; Metformin in OL Period | -1.39 | -0.18 | -0.91 | -0.25 |
Rosiglitazone in DB Period; Metformin in OL Period | 0.95 | 1.61 | 1.81 | 2.05 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 10 days and Week 76 + 10 days
Intervention | percent change (Mean) | |||
---|---|---|---|---|
Femoral neck, n=56, 62 | Total hip, n=56, 62 | Trochanter, n=56, 62 | Lumbar spine, n=55, 62 | |
Metformin in DB Period; Metformin in OL Period | -0.02 | -0.13 | -0.68 | 1.03 |
Rosiglitazone in DB Period; Metformin in OL Period | -0.07 | 0.40 | -0.02 | 0.26 |
BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | |||
---|---|---|---|---|
Femoral neck, n=64, 73 | Total hip, n=64, 73 | Trochanter, n=64, 73 | Lumbar spine, n=65, 70 | |
Metformin in DB Period; Metformin in OL Period | -0.25 | -0.27 | -0.47 | 0.90 |
Rosiglitazone in DB Period; Metformin in OL Period | -0.27 | 0.00 | -0.17 | 0.54 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -1.7 | 4.3 | 10.7 |
Rosiglitazone in DB Period; Metformin in OL Period | -13.2 | -7.4 | -1.3 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
percent change | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -0.46 | 1.21 | -0.27 |
Rosiglitazone in DB Period; Metformin in OL Period | 2.83 | 1.16 | 1.29 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Week 52 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/ vBMD at Week 52 + 30 days x 100% and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
Integral | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -0.20 | 1.15 | -0.06 |
Rosiglitazone in DB Period; Metformin in OL Period | 2.24 | 0.90 | 0.94 |
vBMD (measured in milligrams per centimeters cubed [mg/cm^3]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. (NCT00679939)
Timeframe: Week 52 + 30 days and Week 76 + 30 days
Intervention | percent change (Mean) | ||
---|---|---|---|
percent change | Trabecular | Cortical | |
Metformin in DB Period; Metformin in OL Period | -0.90 | 0.95 | -0.65 |
Rosiglitazone in DB Period; Metformin in OL Period | 2.22 | 1.07 | 0.78 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Week 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 75 | Week 76, GM, n=64, 75 | Week 76, GM + SE, n=64, 75 | |
Metformin in DB Period; Metformin in OL Period | 2.5725 | 6.266 | 10.0934 | -1.9532 | 2.478 | 7.1093 |
Rosiglitazone in DB Period; Metformin in OL Period | -9.9964 | -5.940 | 1.7006 | -0.3232 | 3.687 | 7.8593 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Weel 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 76 | Week 76, GM, n=64, 76 | Week 76, GM + SE, n=64, 76 | |
Metformin in DB Period; Metformin in OL Period | -31.4166 | -17.280 | -0.2292 | 0.4372 | 21.389 | 46.7122 |
Rosiglitazone in DB Period; Metformin in OL Period | -17.0838 | -3.453 | 12.4189 | -16.0971 | 0.215 | 19.6987 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=74, 83 | Week 52, GM, n=74, 83 | Week 52, GM + SE, n=74, 83 | Week 76, GM - SE, n=61, 67 | Week 76, GM, n=61, 67 | Week 76, GM + SE, n=61, 67 | |
Metformin in DB Period; Metformin in OL Period | 4.3929 | 8.146 | 12.0349 | 4.0983 | 9.846 | 15.9116 |
Rosiglitazone in DB Period; Metformin in OL Period | 33.2608 | 37.563 | 42.0049 | -0.2973 | 3.137 | 6.6896 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Baseline, Week 52, and Week 76
Intervention | percent change (Number) | |||||
---|---|---|---|---|---|---|
Week 52, GM - SE, n=74, 82 | Week 52, GM, n=74, 82 | Week 52, GM + SE, n=74, 82 | Week 76, GM - SE, n=64, 75 | Week 76, GM, n=64, 75 | Week 76, GM + SE, n=64, 75 | |
Metformin in DB Period; Metformin in OL Period | -5.8206 | 1.044 | 8.4082 | -8.2870 | -2.932 | 2.7363 |
Rosiglitazone in DB Period; Metformin in OL Period | 14.1569 | 19.689 | 25.4897 | -12.5441 | -8.156 | -3.5470 |
Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | 96.1843 | 173.932 | 282.4903 |
Rosiglitazone in DB Period; Metformin in OL Period | -29.5250 | -3.239 | 32.8525 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -6.9549 | -3.537 | 0.0073 |
Rosiglitazone in DB Period; Metformin in OL Period | 3.1109 | 8.993 | 15.2100 |
Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -5.4666 | -0.975 | 3.7301 |
Rosiglitazone in DB Period; Metformin in OL Period | -7.6337 | -2.683 | 2.5337 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | 29.3058 | 50.823 | 75.9217 |
Rosiglitazone in DB Period; Metformin in OL Period | -15.2056 | 0.513 | 19.1447 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -3.9036 | -0.825 | 2.3517 |
Rosiglitazone in DB Period; Metformin in OL Period | -27.0129 | -24.624 | -22.1566 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data. (NCT00679939)
Timeframe: Week 52 and Week 76
Intervention | percent change (Number) | ||
---|---|---|---|
GM - SE | GM | GM + SE | |
Metformin in DB Period; Metformin in OL Period | -13.9923 | -7.102 | 0.3411 |
Rosiglitazone in DB Period; Metformin in OL Period | -29.0307 | -24.373 | -19.4104 |
Differences in augmentation index (AI, %) using oscillometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
Intervention | percentage of the central pulse pressure (Mean) | |||
---|---|---|---|---|
Baseline | 3 months | 6 months | 12 months | |
Liraglutide | 18 | 15.8 | 13 | 13.9 |
Metformin | 14 | 13.6 | 15 | 15.3 |
Differences in endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. High PBR values represent reduced glycocalyx thickness. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
Intervention | micrometers (Mean) | |||
---|---|---|---|---|
Baseline | 3 months | 6 months | 12 months | |
Liraglutide | 2.1 | 2.07 | 2.5 | 2.04 |
Metformin | 2.13 | 2.15 | 2.13 | 2.10 |
Differences in carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months and 12 months
Intervention | m/s (Mean) | |||
---|---|---|---|---|
Baseline | 3 months | 6 months | 12 months | |
Liraglutide | 11.8 | 11.6 | 10.3 | 10.5 |
Metformin | 11.2 | 11.5 | 11 | 10.8 |
Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with pulse wave velocity (PWV, m/sec) at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. (NCT03010683)
Timeframe: Baseline, 3 months, 6 months, and 12 months.
Intervention | Pearson correlation coefficient (r) (Number) | |||
---|---|---|---|---|
Baseline | 3 months | 6 months | 12 months | |
Liraglutide | 0.39 | 0.36 | 0.32 | 0.44 |
Metformin | 0.35 | 0.32 | 0.29 | 0.37 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 60.3 |
Saxagliptin 10 mg + Metformin | 59.7 |
Metformin | 41.1 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 60.3 |
Saxagliptin 10 mg + Metformin | 59.7 |
Saxagliptin 10 mg | 32.2 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 45.3 |
Saxagliptin 10 mg + Metformin | 40.6 |
Metformin | 29.0 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of Participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 45.3 |
Saxagliptin 10 mg + Metformin | 40.6 |
Saxagliptin 10 mg | 20.3 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 7.5 |
Saxagliptin 10 mg + Metformin | 5.9 |
Metformin | 10.1 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone. (NCT00327015)
Timeframe: Week 24
Intervention | Percentage of participants (Number) |
---|---|
Saxagliptin 5 mg + Metformin | 7.5 |
Saxagliptin 10 mg + Metformin | 5.9 |
Saxagliptin 10 mg | 21.2 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | percent (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Metformin | 9.43 | 7.48 | -1.99 |
Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | mg/dL (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Metformin | 199.1 | 152.7 | -47.3 |
Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | mg/dL (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Saxagliptin 10 mg | 200.9 | 169.9 | -30.9 |
Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | percent (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Saxagliptin 10 mg | 9.61 | 7.86 | -1.69 |
Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | mg*min/dL (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Metformin | 57937 | 42428 | -15005 |
Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
Intervention | mg*min/dL (Mean) | ||
---|---|---|---|
Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
Saxagliptin 10 mg | 57584 | 41229 | -16054 |
Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00103857)
Timeframe: Week 104
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -74.1 |
Metformin 500 mg b.i.d. | -72.7 |
Metformin 1000 mg b.i.d. | -86.7 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -96.2 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -110.0 |
Placebo/Metformin 1000 mg b.i.d. | -93.3 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00103857)
Timeframe: Week 24
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -51.9 |
Metformin 500 mg b.i.d. | -53.4 |
Metformin 1000 mg b.i.d. | -78.0 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -92.5 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -116.6 |
Placebo/Metformin 1000 mg b.i.d. | 0.3 |
Change from baseline at Week 54 is defined as Week 54 minus Week 0. (NCT00103857)
Timeframe: Week 54
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -45.9 |
Metformin 500 mg b.i.d. | -58.6 |
Metformin 1000 mg b.i.d. | -76.3 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -89.6 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -107.9 |
Placebo/Metformin 1000 mg b.i.d. | -80.9 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00103857)
Timeframe: Week 104
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -26.8 |
Metformin 500 mg b.i.d. | -41.4 |
Metformin 1000 mg b.i.d. | -43.2 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -47.5 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -57.3 |
Placebo/Metformin 1000 mg b.i.d. | -45.2 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00103857)
Timeframe: Week 24
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -17.5 |
Metformin 500 mg b.i.d. | -27.3 |
Metformin 1000 mg b.i.d. | -29.3 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -47.1 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -63.9 |
Placebo/Metformin 1000 mg b.i.d. | 5.8 |
Change from baseline at Week 54 is defined as Week 54 minus Week 0. (NCT00103857)
Timeframe: Week 54
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -16.0 |
Metformin 500 mg b.i.d. | -29.0 |
Metformin 1000 mg b.i.d. | -39.6 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -42.5 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -55.6 |
Placebo/Metformin 1000 mg b.i.d. | -43.9 |
HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 104
Intervention | Percent (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -1.15 |
Metformin 500 mg b.i.d. | -1.06 |
Metformin 1000 mg b.i.d. | -1.34 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.39 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.66 |
Placebo/Metformin 1000 mg b.i.d. | -1.39 |
HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 24
Intervention | Percent (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -0.66 |
Metformin 500 mg b.i.d. | -0.82 |
Metformin 1000 mg b.i.d. | -1.13 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.40 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.90 |
Placebo/Metformin 1000 mg b.i.d. | 0.17 |
HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent. (NCT00103857)
Timeframe: Week 54
Intervention | Percent (Least Squares Mean) |
---|---|
Sitagliptin 100 mg q.d. | -0.82 |
Metformin 500 mg b.i.d. | -1.01 |
Metformin 1000 mg b.i.d. | -1.34 |
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | -1.41 |
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | -1.80 |
Placebo/Metformin 1000 mg b.i.d. | -1.10 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
Intervention | nmol/L (Geometric Mean) |
---|---|
Metformin Alone | 1.68 |
Glargine Followed by Metformin | 1.68 |
Placebo | 1.68 |
Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
---|---|
Metformin Alone | 3.53 |
Glargine Followed by Metformin | 3.38 |
Placebo | 3.63 |
Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
Intervention | nmol/L (Geometric Mean) | ||
---|---|---|---|
ACRPg | Steady State C-peptide | ACRPmax | |
Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
Metformin Alone | 1.93 | 11.7 | 13.4 |
Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
Intervention | nmol/L (Geometric Mean) | |
---|---|---|
Steady State C-peptide | ACPRmax | |
Glargine Followed by Metformin | 3.58 | 4.32 |
Liraglutide + Metformin | 3.73 | 4.58 |
Metformin Alone | 3.65 | 4.61 |
Placebo | 3.60 | 4.45 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication [OAM] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks
Intervention | percentage of glycosylated hemoglobin (Least Squares Mean) |
---|---|
1.5 mg LY2189265 | -0.78 |
0.75 mg LY2189265 | -0.71 |
Metformin | -0.56 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication [OAM] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate. (NCT01126580)
Timeframe: Baseline, 52 weeks
Intervention | percentage of glycosylated hemoglobin (Least Squares Mean) |
---|---|
1.5 mg LY2189265 | -0.70 |
0.75 mg LY2189265 | -0.55 |
Metformin | -0.51 |
The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
1.5 mg LY2189265 | 12.92 |
0.75 mg LY2189265 | 12.73 |
Metformin | 12.58 |
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state. (NCT01126580)
Timeframe: 4 weeks, 13 weeks, 26 weeks, and 52 weeks
Intervention | nanogram hours per milliliter (ng*hr/mL) (Mean) |
---|---|
1.5 mg LY2189265 | 12036 |
0.75 mg LY2189265 | 5919 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks plus 30-day follow up
Intervention | participants (Number) |
---|---|
1.5 mg LY2189265 | 0 |
0.75 mg LY2189265 | 0 |
Metformin | 0 |
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks. (NCT01126580)
Timeframe: Baseline through 52 weeks
Intervention | participants (Number) |
---|---|
1.5 mg or 0.75 mg LY2189265 | 10 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | milliliters of mercury (mmHg) (Least Squares Mean) | |||
---|---|---|---|---|
SBP, 26 weeks (n=244, 251, 239) | SBP, 52 weeks (n=221, 219, 215) | DBP, 26 weeks (n=244, 251, 239) | DBP, 52 weeks (n=221, 219, 215) | |
0.75 mg LY2189265 | -2.61 | -2.74 | -1.02 | -1.37 |
1.5 mg LY2189265 | -1.89 | -0.11 | 0.05 | 0.31 |
Metformin | -0.91 | -0.98 | -0.64 | -0.38 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | kilograms per meter squared (kg/m^2) (Least Squares Mean) | |
---|---|---|
26 weeks | 52 weeks | |
0.75 mg LY2189265 | -0.51 | -0.42 |
1.5 mg LY2189265 | -0.86 | -0.73 |
Metformin | -0.82 | -0.83 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | kilograms (kg) (Least Squares Mean) | |
---|---|---|
26 weeks (n=267, 269, 267) | 52 weeks (n=267, 269, 267) | |
0.75 mg LY2189265 | -1.36 | -1.09 |
1.5 mg LY2189265 | -2.29 | -1.93 |
Metformin | -2.22 | -2.20 |
The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | |
---|---|---|
26 weeks (n=195, 200, 211) | 52 weeks (n=197, 200, 212) | |
0.75 mg LY2189265 | -1.75 | -1.71 |
1.5 mg LY2189265 | -1.98 | -1.99 |
Metformin | -1.68 | -1.58 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | milliseconds (msec) (Least Squares Mean) | |||
---|---|---|---|---|
QTcF interval, 26 weeks (n=230, 237, 221) | QTcF interval, 52 weeks (n=212, 212, 205) | PR interval, 26 weeks (n=226, 235, 218) | PR interval, 52 weeks (n=209, 210, 201) | |
0.75 mg LY2189265 | 1.38 | 0.73 | -0.01 | 1.53 |
1.5 mg LY2189265 | 2.60 | 3.76 | -0.04 | 1.15 |
Metformin | -0.91 | -0.53 | -2.04 | -2.88 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | beats per minute (bpm) (Least Squares Mean) | |
---|---|---|
26 weeks (n=230, 237, 221) | 52 weeks (n=212, 212, 205) | |
0.75 mg LY2189265 | 2.57 | 2.36 |
1.5 mg LY2189265 | 1.60 | 2.02 |
Metformin | 0.82 | 1.27 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | |
---|---|---|
26 weeks (n=244, 247, 245) | 52 weeks (n=207, 210, 194) | |
0.75 mg LY2189265 | -1.46 | -1.00 |
1.5 mg LY2189265 | -1.61 | -1.56 |
Metformin | -1.34 | -1.15 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | percentage of HOMA2 (Least Squares Mean) | |||
---|---|---|---|---|
HOMA2-%B, 26 weeks (n=207, 207, 215) | HOMA2-%B, 52 weeks (n=179, 185, 170) | HOMA2-%S, 26 weeks (n=207, 207, 215) | HOMA2-%S, 52 weeks (n=179, 185, 170) | |
0.75 mg LY2189265 | 28.96 | 22.5 | 2.71 | 1.84 |
1.5 mg LY2189265 | 36.55 | 29.97 | 0.95 | 5.29 |
Metformin | 14.11 | 9.77 | 9.99 | 10.83 |
Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | units per liter (U/L) (Median) | |||||
---|---|---|---|---|---|---|
Amylase (total), 26 weeks | Amylase (total), 52 weeks | Amylase (PD), 26 weeks | Amylase (PD), 52 weeks | Lipase, 26 weeks | Lipase, 52 weeks | |
0.75 mg LY2189265 | 6.00 | 5.00 | 4.00 | 3.00 | 5.00 | 5.00 |
1.5 mg LY2189265 | 7.00 | 5.50 | 5.00 | 4.00 | 7.00 | 5.00 |
Metformin | 4.00 | 4.00 | 1.00 | 2.00 | 1.00 | 1.00 |
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | beats per minute (bpm) (Least Squares Mean) | |
---|---|---|
26 weeks (n=244, 251, 239) | 52 weeks (n=221, 219, 215) | |
0.75 mg LY2189265 | 2.14 | 1.63 |
1.5 mg LY2189265 | 2.39 | 1.84 |
Metformin | 1.59 | 1.12 |
(NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | picograms per milliliter (pcg/mL) (Median) | |
---|---|---|
26 weeks | 52 weeks | |
0.75 mg LY2189265 | 0.00 | 0.00 |
1.5 mg LY2189265 | 0.00 | 0.00 |
Metformin | 0.00 | 0.00 |
"The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5=extremely to 1=not at all. For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score." (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | units on a scale (Least Squares Mean) | |
---|---|---|
26 weeks (n=245, 253, 248) | 52 weeks (n=247, 255, 249) | |
0.75 mg LY2189265 | -0.16 | 0.42 |
1.5 mg LY2189265 | 0.24 | 0.49 |
Metformin | 0.41 | 0.59 |
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | units on a scale (Least Squares Mean) | |
---|---|---|
26 weeks (n=244, 249, 241) | 52 weeks (n=245, 251, 244) | |
0.75 mg LY2189265 | 1.81 | 1.29 |
1.5 mg LY2189265 | 1.93 | 1.82 |
Metformin | 2.04 | 1.94 |
"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living [APPADL]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = not at all difficult and 1 = unable to do. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score." (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | units on a scale (Least Squares Mean) | |
---|---|---|
26 weeks (n=247, 251, 247) | 52 weeks (n=247, 252, 248) | |
0.75 mg LY2189265 | 0.19 | -0.05 |
1.5 mg LY2189265 | 0.09 | 0.39 |
Metformin | 0.02 | 0.28 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | units on a scale (Least Squares Mean) | |
---|---|---|
26 weeks (n=248, 254, 249) | 52 weeks (n=249, 255, 250) | |
0.75 mg LY2189265 | 0.63 | 0.61 |
1.5 mg LY2189265 | 0.72 | 0.45 |
Metformin | 0.79 | 0.75 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks plus 30-day follow up
Intervention | participants (Number) | ||
---|---|---|---|
Any CV Event | Any Fatal CV Event | Any Nonfatal CV Event | |
0.75 mg LY2189265 | 2 | 0 | 2 |
1.5 mg LY2189265 | 1 | 0 | 1 |
Metformin | 1 | 0 | 1 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: 26 weeks and 52 weeks
Intervention | participants (Number) | |
---|---|---|
26 weeks | 52 weeks | |
0.75 mg LY2189265 | 150 | 177 |
1.5 mg LY2189265 | 163 | 179 |
Metformin | 151 | 170 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter [mg/dL]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 26 weeks and 52 weeks
Intervention | events (Number) | |||||
---|---|---|---|---|---|---|
Severe, 26 weeks (n=241, 248, 236) | Severe, 52 weeks (n=214, 217, 199) | Documented Symptomatic, 26 weeks (n=241, 248, 236) | Documented Symptomatic, 52 weeks (n=214, 217, 199) | Asymptomatic, 26 weeks (n=241, 248, 236) | Asymptomatic, 52 weeks (n=214, 217, 199) | |
0.75 mg LY2189265 | 0 | 0 | 6 | 8 | 9 | 9 |
1.5 mg LY2189265 | 0 | 0 | 2 | 7 | 19 | 5 |
Metformin | 0 | 0 | 2 | 2 | 13 | 9 |
Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | percentage change in total cholesterol (Median) | |
---|---|---|
26 weeks (n=244, 244, 243) | 52 weeks (n=247, 248, 245) | |
0.75 mg LY2189265 | -1.77 | -0.78 |
1.5 mg LY2189265 | -3.86 | -1.69 |
Metformin | -3.51 | -3.88 |
Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | percentage change in HDL-C (Median) | |
---|---|---|
26 weeks (n=246, 244, 244) | 52 weeks (n=248, 248, 246) | |
0.75 mg LY2189265 | 4.20 | 2.31 |
1.5 mg LY2189265 | 2.39 | 4.95 |
Metformin | 5.78 | 4.32 |
Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | percentage change in LDL-C (Median) | |
---|---|---|
26 weeks (n=233, 231, 221) | 52 weeks (n=236, 240, 231) | |
0.75 mg LY2189265 | -2.70 | -2.34 |
1.5 mg LY2189265 | -6.86 | -2.06 |
Metformin | -8.97 | -7.23 |
Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model. (NCT01126580)
Timeframe: Baseline, 26 weeks, and 52 weeks
Intervention | percentage change in triglycerides (Median) | |
---|---|---|
26 weeks (n=252, 252, 253) | 52 weeks (n=255, 256, 254) | |
0.75 mg LY2189265 | -1.96 | -0.86 |
1.5 mg LY2189265 | -2.35 | -4.27 |
Metformin | 2.56 | 1.91 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model. (NCT01126580)
Timeframe: 26 weeks and 52 weeks
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
HbA1c less than 7%, 26 weeks | HbA1c less than or equal to 6.5%, 26 weeks | HbA1c less than 7%, 52 weeks | HbA1c less than or equal to 6.5%, 52 weeks | |
0.75 mg LY2189265 | 62.6 | 40.0 | 53.2 | 34.7 |
1.5 mg LY2189265 | 61.5 | 46.0 | 60.0 | 42.3 |
Metformin | 53.6 | 29.8 | 48.3 | 28.3 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter [mg/dL]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01126580)
Timeframe: Baseline through 52 weeks
Intervention | events per participant per year (Mean) | ||
---|---|---|---|
Severe | Documented Symptomatic | Asymptomatic | |
0.75 mg LY2189265 | 0.00 | 0.15 | 0.30 |
1.5 mg LY2189265 | 0.00 | 0.62 | 0.24 |
Metformin | 0.00 | 0.09 | 0.18 |
1 review available for carbamates and Stroke
Article | Year |
---|---|
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2020 |
9 other studies available for carbamates and Stroke
Article | Year |
---|---|
Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
Topics: Antiviral Agents; Carbamates; Deglutition Disorders; Drug Combinations; Hepatitis C, Chronic; Hetero | 2020 |
Long-term depression induced by endogenous cannabinoids produces neuroprotection via astroglial CB
Topics: Animals; Astrocytes; Cannabinoids; Carbamates; Long-Term Synaptic Depression; Mice; Neuroprotection; | 2019 |
Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke.
Topics: Animals; Benzodioxoles; Brain Ischemia; Carbamates; Disease Models, Animal; Enzyme Inhibitors; Male; | 2018 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Determination of 18 Types of Amino Acids in the Serum of Ischemic Stroke Patients by High Performance Liquid Chromatography-diode Array Detector Derivatized with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate.
Topics: Amino Acids; Aminoquinolines; Biomarkers; Brain Ischemia; Carbamates; Case-Control Studies; Chromato | 2015 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
Topics: 4-Aminopyridine; Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Corpus Striatu | 2012 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |
Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.
Topics: Apoptosis; Carbamates; Caspase Inhibitors; Cell Line; Dipeptides; Humans; Inhibitory Concentration 5 | 2004 |